tradingkey.logo
tradingkey.logo
Search

Fulgent Genetics Inc

FLGT
Add to Watchlist
20.850USD
+0.030+0.14%
Close 07/02, 13:00ETQuotes delayed by 15 min
601.54MMarket Cap
LossP/E TTM

Fulgent Genetics Inc

20.850
+0.030+0.14%
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

+0.14%

5 Days

+4.46%

1 Month

+6.92%

6 Months

-18.52%

Year to Date

-20.63%

1 Year

+3.94%

Key Figures
21.000Open
21.180High
184.53KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.64%Turnover Ratio
20.820Prev. Close
20.535Low
2.81MTurnover
LossP/E Static
0.57P/B
0.00%Div Yield TTM
-6.35%ROA
31.04052wk High
1.01Volume Ratio
-42.71MNet Profit
28.85MShares
-2.3961EPS TTM
0.93Beta
-6.78%ROE
13.46052wk Low
3.10%Amplitude
27.35%Gross Margin
601.54MMarket Cap
2.62Reward/Risk
2.58%Risk Rate

TradingKey Stock Score of Fulgent Genetics Inc

Currency: USD Updated: 2026-07-02

Key Insights

Fulgent Genetics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 40 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 15.00.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Fulgent Genetics Inc's Score

Industry at a Glance

Industry Ranking
40 / 75
Overall Ranking
165 / 4565
Industry
Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Fulgent Genetics Inc Highlights

StrengthsRisks
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Fairly Valued
The company’s latest PE is -8.70, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 18.21M shares, decreasing 7.22% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 46.95K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.10.

Analyst Rating

Based on 1 analysts
Hold
Current Rating
15.000
Target Price
-27.95%
Upside Space

Fulgent Genetics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Fulgent Genetics Inc Info

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Ticker SymbolFLGT
CompanyFulgent Genetics Inc
CEOHsieh (Ming)
Websitehttps://www.fulgentgenetics.com/

FAQs

What is the current price of Fulgent Genetics Inc (FLGT)?

The current price of Fulgent Genetics Inc (FLGT) is 20.85.

What is the symbol of Fulgent Genetics Inc?

The ticker symbol of Fulgent Genetics Inc is FLGT.

What is the 52-week high of Fulgent Genetics Inc?

The 52-week high of Fulgent Genetics Inc is 31.04.

What is the 52-week low of Fulgent Genetics Inc?

The 52-week low of Fulgent Genetics Inc is 13.46.

What is the market capitalization of Fulgent Genetics Inc?

The market capitalization of Fulgent Genetics Inc is 601.54M.

Is Fulgent Genetics Inc (FLGT) currently rated as Buy, Hold, or Sell?

According to analysts, Fulgent Genetics Inc (FLGT) has an overall rating of signal_hold, with a price target of 15.00.

What is the Earnings Per Share (EPS TTM) of Fulgent Genetics Inc (FLGT)?

The Earnings Per Share (EPS TTM) of Fulgent Genetics Inc (FLGT) is -1.97.